Ina L. Deras

1.7k total citations
15 papers, 1.3k citations indexed

About

Ina L. Deras is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Ina L. Deras has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Ina L. Deras's work include Prostate Cancer Diagnosis and Treatment (8 papers), Prostate Cancer Treatment and Research (7 papers) and Cancer Genomics and Diagnostics (5 papers). Ina L. Deras is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (8 papers), Prostate Cancer Treatment and Research (7 papers) and Cancer Genomics and Diagnostics (5 papers). Ina L. Deras collaborates with scholars based in United States, Canada and United Kingdom. Ina L. Deras's co-authors include Jack Groskopf, Harry G. Rittenhouse, Amy Blase, Leonard S. Marks, Sheila M. J. Aubin, Yves Fradet, William J. Ellis, Seongjoon Koo, Alan W. Partin and John Day and has published in prestigious journals such as Cancer Research, The Journal of Urology and Annals of Oncology.

In The Last Decade

Ina L. Deras

15 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ina L. Deras United States	6	992	488	446	158	147	15	1.3k
Ben Andrews United States	6	331 0.3×	231 0.5×	213 0.5×	26 0.2×	145 1.0×	7	685
Phataraporn Thorson United States	10	380 0.4×	106 0.2×	153 0.3×	178 1.1×	86 0.6×	13	547
A E Katz United States	9	390 0.4×	93 0.2×	182 0.4×	108 0.7×	73 0.5×	10	529
Jeffrey P. Simko United States	11	359 0.4×	131 0.3×	153 0.3×	31 0.2×	62 0.4×	16	629
Prabhakar Pandey United States	11	299 0.3×	174 0.4×	200 0.4×	95 0.6×	72 0.5×	15	584
Curtis Dunshee United States	11	424 0.4×	130 0.3×	107 0.2×	20 0.1×	73 0.5×	41	548
Ding-Wei Ye China	12	267 0.3×	157 0.3×	207 0.5×	59 0.4×	126 0.9×	20	509
Francesca Vignani Italy	14	509 0.5×	186 0.4×	187 0.4×	11 0.1×	125 0.9×	46	750
Ken-ichi Tobisu Japan	10	252 0.3×	108 0.2×	164 0.4×	44 0.3×	107 0.7×	17	438
Richard Sorace United States	9	303 0.3×	221 0.5×	47 0.1×	32 0.2×	56 0.4×	17	590

Countries citing papers authored by Ina L. Deras

Since Specialization

Citations

This map shows the geographic impact of Ina L. Deras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ina L. Deras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ina L. Deras more than expected).

Fields of papers citing papers by Ina L. Deras

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ina L. Deras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ina L. Deras. The network helps show where Ina L. Deras may publish in the future.

Co-authorship network of co-authors of Ina L. Deras

This figure shows the co-authorship network connecting the top 25 collaborators of Ina L. Deras. A scholar is included among the top collaborators of Ina L. Deras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ina L. Deras. Ina L. Deras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Barrett, J. Carl, Kelli Bramlett, Darya Chudova, et al.. (2020). Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group. Clinical Chemistry. 66(9). 1156–1166. 62 indexed citations

Baden, Jonathan, Chen Zhao, James Pratt, et al.. (2019). Comparison of platforms for determining tumour mutational burden (TMB) in patients with non-small cell lung cancer (NSCLC). Annals of Oncology. 30. v25–v25. 2 indexed citations

Zhang, Shile, Phillip Le, Christine Glidewell-Kenney, et al.. (2018). Abstract 3414: Determining microsatellite instability (MSI) status of colorectal cancers through next-generation sequencing (NGS). Cancer Research. 78(13_Supplement). 3414–3414. 1 indexed citations

Deras, Ina L., Aaron Wise, Chen Zhao, et al.. (2017). Abstract 3585: Determination of gene amplifications with a next-generation sequencing cancer panel. Cancer Research. 77(13_Supplement). 3585–3585. 1 indexed citations

Sherwood, James, Helen Brown, Amelie Schreieck, et al.. (2017). Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice. ESMO Open. 2(4). e000235–e000235. 8 indexed citations

Deras, Ina L., Sheila M. J. Aubin, Amy Blase, et al.. (2008). PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. The Journal of Urology. 179(4). 1587–1592. 343 indexed citations

Marks, Leonard S., Yves Fradet, Ina L. Deras, et al.. (2007). PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy. Urology. 69(3). 532–535. 335 indexed citations

Partin, Alan W., Leslie A. Mangold, Robin Gurganus, et al.. (2007). 1623: Biological Variation of PCA3 Score in Men Previously Diagnosed with Prostate Cancer. The Journal of Urology. 177(4S). 538–538. 3 indexed citations

Sokoll, Lori J., William Ellis, Paul H. Lange, et al.. (2007). A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clinica Chimica Acta. 389(1-2). 1–6. 87 indexed citations

10.

Groskopf, Jack, Ina L. Deras, Amy Blase, et al.. (2007). 1709: The PCA3 Score is Independent of Prostate Gland Volume, and Can Synergize with other Patient Information for Predicting Biopsy Outcome. The Journal of Urology. 177(4S). 568–568. 1 indexed citations

11.

Groskopf, Jack, Amy Blase, Seongjoon Koo, et al.. (2007). 102 THE PCA3 SCORE IS INDEPENDENT OF PROSTATE GLAND VOLUME, AND CAN SYNERGIZE WITH OTHER PATIENT INFORMATION FOR PREDICTING BIOPSY OUTCOME. European Urology Supplements. 6(2). 48–48. 3 indexed citations

12.

Marks, Leonard S., Sheila M. J. Aubin, Ina L. Deras, et al.. (2006). 540: Specificity of the Aptima® PCA3 Assay for Prostate Cancer. The Journal of Urology. 175(4S). 175–176. 1 indexed citations

13.

Groskopf, Jack, Ina L. Deras, Amy Blase, et al.. (2006). SPECIFICITY OF THE APTIMA® PCA3 ASSAY FOR PROSTATE CANCER. European Urology Supplements. 5(2). 240–240. 1 indexed citations

14.

Fradet, Yves, Jack Groskopf, Ina L. Deras, et al.. (2006). APTIMA® PCA3 MOLECULAR URINE TEST: DEVELOPMENT OF A METHOD TO AID IN THE DIAGNOSIS OF PROSTATE CANCER. European Urology Supplements. 5(2). 275–275. 2 indexed citations

15.

Groskopf, Jack, Sheila M. J. Aubin, Ina L. Deras, et al.. (2006). APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer. Clinical Chemistry. 52(6). 1089–1095. 411 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact